Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?Zacks Investment Research • 03/15/23
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/10/23
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyGlobeNewsWire • 03/04/23
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyGlobeNewsWire • 02/21/23
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/17/23
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & HepatologyGlobeNewsWire • 12/12/22
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/22
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022GlobeNewsWire • 11/05/22
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceGlobeNewsWire • 10/13/22
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022GlobeNewsWire • 08/26/22
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASHGlobeNewsWire • 08/18/22
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/22
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 07/05/22
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 06/29/22
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 06/28/22